Clinical Trial Update: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial update tests atezolizumab with or without eribulin mesylate in patients with recurrent locally advanced or metastatic urothelial carcinoma, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma
• Renal Pelvis Urothelial Carcinoma
• Unresectable Urothelial Carcinoma
• Ureter Urothelial Carcinoma
• Urethral Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING